NCT04942184

Brief Summary

Memory mistakes are one of the most detrimental symptoms in Alzheimer's Disease (AD). In this study the investigators will measure the long-term efficacy of memory strategies in patients with AD. First, the efficacy of the strategies will be evaluated in the laboratory by analyzing the behavioral response and the brain activity of the patients. During the first visit, patients will be taught the memory strategies and asked to repeat them at home for 4 weeks. During this period of time, patients will perform several memory tasks while their performance and brain activity will be measured using portable devices. Monitoring brain activity and behavioral responses to memory tasks will provide insightful information on the efficacy of the strategies and allow the investigation of how patients can maintain the strategies over time. The research will examine if improving memory through the use of cognitive strategies, can positively affect other domains of daily life.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2022

Shorter than P25 for not_applicable alzheimer-disease

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2021

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 28, 2021

Completed
1.3 years until next milestone

Study Start

First participant enrolled

October 1, 2022

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2023

Completed
Last Updated

November 1, 2022

Status Verified

October 1, 2022

Enrollment Period

8 months

First QC Date

June 9, 2021

Last Update Submit

October 28, 2022

Conditions

Keywords

MemoryMemory StrategiesEEG headgear

Outcome Measures

Primary Outcomes (1)

  • Change in performance in memory tasks over time

    Change in performance in memory tasks will be measured through daily at home memory exercises that will last from 20 minutes to 1 hour. Higher the scores on the exercise represent better memory performance.

    baseline, 4 weeks

Secondary Outcomes (8)

  • Change in electroencephalogram (EEG) early negative frontal component (N400)

    Baseline, 4 weeks

  • Change in EEG Late Positive Parietal Component (LPC)

    Baseline, 4 weeks

  • Change in EEG Late Positive Frontal Effect (LFE)

    Baseline, 4 weeks

  • Neuropsychological assessment using the Montreal Cognitive Assessment (MoCA)

    baseline, 4 weeks

  • Neuropsychological assessment using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).

    Baseline, 4 weeks

  • +3 more secondary outcomes

Study Arms (2)

Group 1- 15 Mild AD and 15 MCI due to AD

EXPERIMENTAL

In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.

Behavioral: Memory strategies in Arm 1Device: Electroencephalogram (EEG) headset in Arm 1Other: Tablet in Arm 1

Group 2- 15 Mild AD and 15 MCI due to AD

ACTIVE COMPARATOR

In Group 2, for the first 2 weeks participants will be reminded to "try hard" to remember the items although they will not be given any specific strategies. At week 2 the subjects will be taught memory strategies and reminded to use them each day from week 2 to week 4.

Behavioral: Memory strategies in Arm 2Device: Electroencephalogram (EEG) headset in Arm 2Other: Tablet in Arm 2

Interventions

Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.

Group 1- 15 Mild AD and 15 MCI due to AD

A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.

Group 1- 15 Mild AD and 15 MCI due to AD

A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.

Group 1- 15 Mild AD and 15 MCI due to AD

Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.

Group 2- 15 Mild AD and 15 MCI due to AD

A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.

Group 2- 15 Mild AD and 15 MCI due to AD

A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.

Group 2- 15 Mild AD and 15 MCI due to AD

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For Mild Alzheimer Disease (AD) dementia
  • meets probable AD dementia National Institute on Aging and Alzheimer's Association (NIA-AA) criteria
  • Mini-Mental State Examination (MMSE) 20-27
  • performance on delayed recall and recognition memory worse than 1.5 standard deviation (SD) for age and education
  • performance on delayed recall and recognition memory worse than 1.5 SD for age \& education in at least one other cognitive domain (e.g., language, executive functioning) based on other tests in our neuropsychological test battery.
  • Dr. Turk and Dr. Budson will confirm all mild AD dementia diagnoses
  • For Mild cognitive impairment (MCI)
  • meets MCI due to AD NIA-AA criteria
  • MMSE \> 23
  • performance on delayed recall and recognition memory worse than 1.0 SD for age \& education adjusted norms
  • Dr. Turk and Dr. Budson will confirm all MCI due to AD diagnoses

You may not qualify if:

  • A clinically significant problem of any of the following conditions:
  • depression
  • heavy alcohol or drug use
  • cerebrovascular disease
  • traumatic brain damage
  • a different degenerative disease (e.g., fronto-temporal dementia, Parkinson's disease)
  • any medical condition whose severity could significantly impair cognition (e.g., organ failure)
  • Unable to understand the consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Alzheimer DiseaseDementiaLymphoma, FollicularCognitive Dysfunction

Interventions

ElectroencephalographyTablets

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesCognition Disorders

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, NeurologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosisDosage FormsPharmaceutical Preparations

Study Officials

  • Katherine Turk, MD

    BU School of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2021

First Posted

June 28, 2021

Study Start

October 1, 2022

Primary Completion

June 1, 2023

Study Completion

June 1, 2023

Last Updated

November 1, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share